Skip to main content
SpringerLink
Log in

Trans-arterial p53-Gene-Embolization with Gelatin Sponge Microparticles for Hepatocellular Carcinoma with BCLC Stage B: Single-Center Experience

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Trans-arterial chemoembolization for hepatic cellular carcinoma (HCC) is a recommended treatment schedule for stage B patients under the Barcelona-Clinic Liver Cancer (BCLC) diagnostic and treatment strategy system. Data from treatments with embolization performed with different embolizing microparticle reagents either alone or in combination with different chemotherapeutic agents showed favorable safety profile and significant efficacy in tumor control. In addition, recombinant adenoviral human p53 gene (rAd-p53) therapy has been shown effective in the treatment of many solid tumors and some pre-cancerous lesions such as oral leukoplakia, while also presenting a favorable safety profile. To date, no data are available regarding the safety and efficacy of trans-catheter treatment of HCC with embolizing microparticles combined with rAd-p53 in the world. In this study, we demonstrated the safety and efficacy of trans-arterial embolization combined with rAd-p53 gene therapy (TAGE) in the treatment of patients with BCLC stage B HCC. In this retrospective study, 15 HCC patients with BCLC stage B were received TAGE. Fifteen males were included with an average age of 65 (53–89) years and with Child-Pugh score A or B (12 or 3, respectively). The embolic agent used in TAE was gelatin sponge microparticles of diameter 350–560 µm, and 3–5 × 1012 viral of rAd-p53 was diluted with physiological saline into 15 ml suspension. The study endpoints included response rate, 1 year survival, liver function, and adverse effects. With a median follow-up time of 15.5 months, 15 HCC patients received a total number of 64 TAGE treatments without any significant complication. Based on the modified response evaluation criteria in solid tumors, complete response (CR) was observed in four, six, and six patients at 1, 3, and 6 months after the first treatment, respectively. The objective tumor response (CR + PR) rates at 1, 3, and 6 months were 100.0, 93.3, and 80.0 %. The total survival rates of 6 and 12 months in 15 patients were 100 %, 100 % respectively. The median survival time was 32 months in all. Mild or median fever was observed in all 15 patients, which occurred 4–12 h after treatment and lasted for 12–24 h. Transient abdominal pain, nausea, and cholecystitis were the common side effects with a frequency of 46.7, 33.3, and 26.7 %, respectively, and three cases (20 %) showed decrease in platelet count. However, other severe (grade 3 or 4) adverse events associated with TAGE were not observed. TAGE is a safe and effective treatments for HCC with BCLC stage B HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].

  2. Wang, X. W., Gibson, M. K., Vermeulen, W., et al. (1995). Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer, 55, 6012–6016.

    CAS  Google Scholar 

  3. Hsia, C. C., Nakashima, Y., Thorgeirsson, S. S., et al. (2000). Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncology Reports, 7, 353–356.

    CAS  PubMed  Google Scholar 

  4. Honda, K., Sbisa`, E., Tullo, A., et al. (1998). p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. British Journal of Cancer, 77, 776–782.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: an update. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology, 53, 1020–1022.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Huang, M., & Liu, G. (1999). The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett, 135, 97–105.

    Article  CAS  PubMed  Google Scholar 

  7. Kato, A., Miyazaki, M., Ambiru, S., et al. (2001). Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. Journal of Surgical Oncology, 78, 110–115.

    Article  CAS  PubMed  Google Scholar 

  8. Kuo, M. T., Zhao, J. Y., Teeter, L. D., et al. (1992). Activation of multidrug resistance (Pglycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth and Differentiation, 3, 531–540.

    CAS  PubMed  Google Scholar 

  9. Marelli, L., Stigliano, R., Triantos, C., et al. (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovascular and Interventional Radiology, 30, 6–25.

    Article  PubMed  Google Scholar 

  10. Lane, D. P., Fang, C., & Lain, C. S. (2010). p53-based Cancer Therapy. Cold Spring Harbor Perspectives in Biology,. doi:10.1101/cshperspect.a001222originallypublishedonlineMay,122010.

    Google Scholar 

  11. Peng, Z. (2005). Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Human Gene Therapy, 16, 1013–1024.

    Google Scholar 

  12. Schuler, M., Bossy-Wetzel, E., Goldstein, J. C., et al. (2000). p53 induces apoptosis by caspase activation throμgh mitochondrial cytochromec release. Journal of Biological Chemistry, 275, 7337–7342.

    Article  CAS  PubMed  Google Scholar 

  13. Soengas, M. S., Alarcón, R. M., Yoshida, H., et al. (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science, 284, 156–159.

    Article  CAS  PubMed  Google Scholar 

  14. Muller, M., Strand, S., Hμg, H., et al. (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95(APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Journal of Clinical Investigation, 99, 403–413.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Yu, M., Chen, W., & Zhang, J. (2010). p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma. Anti-Cancer Drugs, 21, 882–884.

    Article  CAS  PubMed  Google Scholar 

  16. Yang, Z. X., Wang, D., Wang, G., et al. (2010). Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 136, 625–630.

    Article  PubMed  Google Scholar 

  17. Tian, G., Liu, J., Zhou, J. S., et al. (2009). Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A pilot phase II trial. Anti-Cancer Drugs, 20, 389–395.

    Article  CAS  PubMed  Google Scholar 

  18. Guan, Y. S., Liu, Y., Zhou, X. P., et al. (2005). P53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. Gut, 54, 1318–1319.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Rand, T., Loewe, C., Schoder, M., & Schmook, M. T. (2005). Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovascular and Interventional Radiology, 28, 313–318.

    Article  PubMed  Google Scholar 

  20. Brown, D. B., Pilgram, T. K., & Darcy, M. D. (2005). Hepatic arterial chemoembolization for hepatocellular carcinoma: Comparison of survival rates with different embolic agents. Journal of Vascular and Interventional Radiology, 16, 1661–1666.

    Article  PubMed  Google Scholar 

  21. Lammer, J., Malagari, K., Vogl, T., et al. (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and Interventional Radiology, 33, 41–52.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Song, M. J., Park, C.-H., Kim, J. D., et al. (2011). Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: A case–control study of Asian patients. European Journal of Gastroenterology and Hepatology, 23, 521–527.

    Article  CAS  PubMed  Google Scholar 

  23. Vogl, T. J., Lammer, J., Lencioni, R., et al. (2011). Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with precision TACE With drug-eluting beads: Results from the precision V randomized trial. American Journal of Roentgenology, 197, 562–570.

    Article  Google Scholar 

  24. Zhao, G. S., Liu, Y., Zhang, Y. W., et al. (2013). Huaier granules combined with intraarterial chemoembolization for the treatment of hepatocellular carcinoma. Chinese Journal of General Surgery, 28, 440–443.

    Google Scholar 

  25. Li, C., Zhang, Y. W., Zhou, J., et al. (2013). Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World Journal of Surgical Oncology, 11, 222.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Zhang, Y. W., & Liu, Y. (2013). Transcatheter arterial chemoembolization of hepatocellular carcinoma with 350–560 μm gelatin sponge particles: Efficacy, tumour response and survival.Chin. Journal of Hepatology, 21, 637–638.

    Google Scholar 

  27. Eisenhauer, E. A., Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228–247.

    Article  CAS  PubMed  Google Scholar 

  28. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.

  29. Sergio, A., Cristofori, C., Cardin, R., et al. (2008). Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. American Journal of Gastroenterology, 103, 914–921.

    Article  PubMed  Google Scholar 

  30. Fujiwara, T., Nishizaki, M., & Tanaka, N. (2000). Recombinant adenovirus expressing wild-type p53 is antiagiogenic: Implication for lung cancer gene therapy. Gan To Kagaku Ryoho, 27, 1217–1224.

    CAS  PubMed  Google Scholar 

  31. Zhang, L., Yu, D., Hu, M., et al. (2000). Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Research, 60, 3655–3661.

    CAS  PubMed  Google Scholar 

  32. Nishizaki, M., Fujiwara, T., Tanida, T., et al. (1999). Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clinical Cancer Research, 5, 1015–1023.

    CAS  PubMed  Google Scholar 

  33. Riccioni, T., Cirielli, C., Wang, X., et al. (1998). Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Therapy, 5, 747–754.

    Article  CAS  PubMed  Google Scholar 

  34. Pan, J. J., Zhang, S. W., Chen, C. B., et al. (2009). Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. Journal of Clinical Oncology, 27, 799–804.

    Article  PubMed  Google Scholar 

  35. Miao, Yu., Chen, Wei, Zhang, Jinshan, et al. (2010). P53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma. Anti-Cancer Drugs, 21, 882–884.

    Article  Google Scholar 

  36. Atencio, I. A., Grace, M., Bordens, R., et al. (2006). Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a phase 1 colorectal cancer trial. Cancer Gene Therapy, 13, 169–181.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    Ying Liu, Yuewei Zhang, Shunxiong Tang, Jun Zhou, Chuang Li & Guangsheng Zhao

  2. Sibiono Genetech Ltd. High Tech Industrial Park, Technology Central 1 Road No.19, Shenzhen, 518057, Guangdong, China

    Dody Bautista

  3. York University, 190 Albany, Suite 215 York University 4700 Keele St, Toronto, ON, M3J1p3, Canada

    Dody Bautista

Authors
  1. Ying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuewei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dody Bautista
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shunxiong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chuang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guangsheng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yuewei Zhang or Dody Bautista.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Zhang, Y., Bautista, D. et al. Trans-arterial p53-Gene-Embolization with Gelatin Sponge Microparticles for Hepatocellular Carcinoma with BCLC Stage B: Single-Center Experience. Cell Biochem Biophys 71, 99–104 (2015). https://doi.org/10.1007/s12013-014-0167-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0167-2

Keywords

Search

Navigation